Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congress Set To Approve CR, Freezing FDA Spending Level For Next Three Months

Device center requests to beef up AI and medtech safety measures will be put on hold by continuing resolution

Executive Summary

The US agency’s 2021 device funding request for $21m above its 2020 budget will be frozen under a continuing resolution, making planning difficult.

You may also be interested in...



US CMS Extends COVID-19-Related Loan Repayment Period For Health Care Suppliers

Durable medical equipment suppliers and other health care providers borrowing money from CMS for the pandemic get the loans’ repayment periods extended beyond an August 2020 start.

Pressure On Medtech Companies High, And Recalls Frequent, Amidst COVID-19

Medical device manufacturers are operating in what may be the industry’s most challenging business and regulatory environment in recent history, attorneys Bill McConagha and Pamela Amaechi argue in this guest article.

HHS Advances AI Priorities In Budget Ask

The US Department of Health and Human Services is asking Congress for $10m in its latest budget request specifically to advance the use of artificial intelligence to regulate FDA products and promote development of AI technology. The ask aligns with President Trump’s vision for government agencies to help make the US a leader in AI and machine learning products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT142812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel